Chiesi presents 2021 results as group moves into biologics

Privately-held Italian drugmaker Chiesi has reported strong financial results for 2021, with revenues of 2.42 billion euros ($2.65 billion), an increase of 8.6% from the year before.

The company said it had achieved growth in its gross operating profit (EBITDA) of 3.9%, leading to a net financial position at the end of the year of up to a billion euros, a "substantial increase" on the year before.

While Europe remains by far the company’s most significant market, it has worked to globalize its presence, with strong international growth of 8.6% and growth in China of 22%.